DAX-1,11 % EUR/USD-0,08 % Gold-0,16 % Öl (Brent)+0,64 %

Roche reports a strong start in 2019 and raises the outlook for the full-year

Nachrichtenquelle: GlobeNewswire
17.04.2019, 07:00  |  391   |   |   

F. Hoffmann-La Roche Ltd / Roche reports a strong start in 2019 and raises the outlook for the full-year . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

Basel, 17 April 2019

  • Group sales increase 8%1 at constant exchange rates and 9% in Swiss francs

  • Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq

  • Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor

  • Important approvals in the first quarter. In the US: Tecentriq combination therapy for extensive-stage small cell lung cancer; Tecentriq combination therapy for triple-negative breast cancer and companion diagnostic test; Herceptin Hylecta for subcutaneous injection for breast cancer; in the EU: Hemlibra for people with severe haemophilia A without factor VIII inhibitors; Tecentriq plus Avastin combination therapy for initial treatment of a form of lung cancer

  • Outlook raised for 2019 to mid-single digit sales growth

Sales CHF millions As % of sales % change
January - March 2019 2019 2018 2019 2018 At CER In CHF
Group sales 14,826 13,583 100.0 100.0 +8 +9
             
Pharmaceuticals Division 11,927 10,672 80.4 78.6 +10 +12
United States 6,623 5,516 44.7 40.6 +14 +20
Europe 2,101 2,287 14.2 16.8 -6 -8
Japan 941 851 6.3 6.3 +7 +11
International* 2,262 2,018 15.2 14.9 +17 +12
             
Diagnostics Division 2,899 2,911 19.6 21.4 +1 0
*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others    

Commenting on the Group's sales, Roche CEO Severin Schwan said: "We have started the year with strong sales growth, driven by the newly launched products in our Pharmaceuticals Division. Demand for our new medicines remains high. Health authorities granted a number of important approvals for our medicines in the first quarter. These include the first cancer immunotherapies for triple-negative breast cancer and small cell lung cancer, two diseases with high unmet patient need. Based on our performance in the first quarter, we raise the outlook for the full-year."

Seite 1 von 9
Wertpapier
Roche Holding
Mehr zum Thema
EuroChinaJapanCHFChile


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
16.05.19
16.05.19
14.05.19
14.05.19
10.05.19
08.05.19
08.05.19
07.05.19
06.05.19
29.04.19